Equities Analysts Set Expectations for Jazz Pharmaceuticals plc’s Q3 2024 Earnings (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Equities researchers at Zacks Research upped their Q3 2024 EPS estimates for shares of Jazz Pharmaceuticals in a note issued to investors on Wednesday, August 21st. Zacks Research analyst S. Ganoria now expects that the specialty pharmaceutical company will post earnings per share of $4.34 for the quarter, up from their prior forecast of $4.25. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $15.31 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q4 2024 earnings at $4.83 EPS, FY2024 earnings at $15.71 EPS, Q1 2025 earnings at $3.13 EPS, Q2 2025 earnings at $4.08 EPS, Q3 2025 earnings at $4.34 EPS, Q4 2025 earnings at $4.53 EPS, FY2025 earnings at $16.07 EPS, Q1 2026 earnings at $3.75 EPS, Q2 2026 earnings at $4.30 EPS and FY2026 earnings at $17.58 EPS.

JAZZ has been the topic of a number of other research reports. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Piper Sandler decreased their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Finally, Barclays decreased their target price on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Friday, May 3rd. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $173.07.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $113.87 on Monday. The stock has a market capitalization of $7.18 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 1.76 and a beta of 0.58. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $146.70. The firm’s 50 day simple moving average is $109.11 and its 200-day simple moving average is $112.99. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 1.90.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rise Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc lifted its holdings in Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in Jazz Pharmaceuticals in the 2nd quarter valued at $29,000. EverSource Wealth Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.